Investor Presentaiton

1H FY23 FINANCIAL HIGHLIGHTS 19.2% growth in operating revenue reflects slow gradual recovery in patient volumes from the COVID-19 pandemic and the acquisition of the X-Ray Group, Peloton Radiology and Horizon Radiology 58.2% increase in statutory 36.4% decline in 2.4% increase in 48.0% decline in operating operating operating 19.2% increase in operating 56.0% increase Net debt / in EBITDA (pre-AASB NPAT NPAT EBITDA diluted EPS revenue free cash 16) flow $16.1m $7.8m $39.8m 3.3 cps $215.1m 38.5m 3.1x A challenging 1H FY23 result driven by: Slow gradual recovery of patient volumes. Further recovery expected to drive positive operating leverage and improved profitability over time Limited price increases with Medicare indexation of 1.6% well below inflation. No inflation adjustment from the Accident Compensation Corporation (ACC) and District Health Boards (DHBs) and limited inflation indexation from private health insurers in New Zealand. Selective price increases taken where possible while remaining market competitive Significant cost pressures, especially higher labour costs, driven by inflation and labour market supply constraints, together with higher interest funding costs. Management are focused on containing and reducing costs wherever possible Operating EBITDA margin decrease of 300 bps compared to the prior corresponding period (230 bps compared to FY22). Both Peloton Radiology and Horizon Radiology acquisitions experiencing similar volume trends as IDX's existing businesses in both QLD and NZ respectively Statutory NPAT of $16.1 million after writeback of non-operating provisions, transaction and integration costs, amortisation of customer contracts and other costs, net of tax, of $8.3 million The Group declared a fully franked interim dividend of 2.5 cps (1H FY22 4.0 cps), representing 74.4% of Operating NPAT idx

View entire presentation